<DOC>
	<DOCNO>NCT00000927</DOCNO>
	<brief_summary>The purpose study see safe use BufferGel vagina woman HIV low risk get HIV . Many new case HIV result heterosexual activity . Condom use currently effective way prevent spread HIV sexually transmit disease ( STDs ) . However , woman , great risk get HIV , often unable convince partner use condom . Therefore , important develop method prevent spread HIV control woman , medicine use vagina . BufferGel know kill organism cause STDs , include HIV . BufferGel may without cause genital irritation sore medicine . More study need see true .</brief_summary>
	<brief_title>A Study BufferGel Women</brief_title>
	<detailed_description>Heterosexual transmission HIV presently account vast majority new HIV infection worldwide . Currently condom method available show effective HIV sexually transmit disease ( STDs ) . However , woman great risk acquire HIV often unable negotiate condom use . Therefore , important effective female-controlled barrier method , topical microbicides , make available woman . BufferGel sufficient buffer capacity acidify twice volume human semen , inactivates STD pathogen , include HIV . Unlike topical microbicides , BufferGel non-detergent cause genital irritation lesion . The safety acceptability BufferGel still need study carefully . Participants divide two cohort . Cohort IA consist sexually abstinent woman cohort IB consist sexually active woman . Within U.S. cohort , participant assign apply BufferGel either twice daily . Within international cohort , participant apply BufferGel twice daily . Participants apply BufferGel 14 day . Pelvic examination perform Days 7 14 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion Criteria All participant must : HIVnegativity license EIA . Willingness ability complete study diary . A regular menstrual cycle minimum 18 day menses . Ability insert BufferGel daily require protocol . Cohort IA participant must : Agree abstain sexual intercourse duration study . Cohort IB participant must : Agree vaginal intercourse least 2 time per week use nonlubricated condom act intercourse . Have currently ( 3 month longer ) single sexual partner lowrisk HIV infection . Exclusion Criteria Coexisting Condition : Participants follow condition symptom exclude : A Grade 3 high liver , renal , hematology abnormality . Menopausal . Breakthrough menstrual bleeding . Any STD symptom , see pelvic exam , consistent STD genital tract infection trauma include vaginitis , cervicitis , edema , erythema , ecchymosis , petechial hemorrhage , vulvar cervicovaginal lesion abrasion , subepithelial hemorrhage , sign genital tract infection ( asymptomatic bacterial vaginosis ) laboratory evaluation . Concurrent Medication : Excluded : Any vaginal product BufferGel , include lubricant feminine hygiene product . Vaginal drying agent . Douche . Participation microbicide contraceptive study . Treatment STD . Participants follow prior condition exclude : IUD , abnormal PAP smear , pregnancy , abortion , gynecologic surgery last 3 month . Any following side effect relate Depoprovera use past 2 month : headache , dizziness , abdominal pain , fatigue , nervousness . Prior Medication : Excluded : A course antibiotic therapy ( treatment malaria ) last 14 day . Any spermicide within past month . Initiation Depoprovera contraceptive purpose last 6 month . Risk Behavior : Excluded : Use intravenous drug currently within past year .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 1999</verification_date>
	<keyword>Administration , Topical</keyword>
	<keyword>Mucous Membrane</keyword>
	<keyword>Anti-Infective Agents</keyword>
	<keyword>Cervix Uteri</keyword>
	<keyword>Vagina</keyword>
	<keyword>Vulva</keyword>
	<keyword>Buffers</keyword>
</DOC>